Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.